CTRI/2020/07/026534
Not yet recruiting
Phase 3
Evaluation of clinical efficacy of antiviral nutraceutical PICOVRID in COVID-19 positive patients
Indian Institute of Technology Bombay0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Indian Institute of Technology Bombay
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Individuals COVID\-19 positive in last 3 days
- •2\. Patients with mild COVID\-19 illness as defined in the MOHFW guidelines i.e. fever and or upper respiratory tract infection ,influenza like illness
- •3\. Patients agreeing to provide a written informed consent
- •4\. Patients who agree to reside in the COVID 19 facility during the study
Exclusion Criteria
- •1\. Patients with moderate or severe COVID 19 at the time of recruitment
- •2\. Patients not able to consume drugs orally
- •3\. Patients with uncontrolled hypertension or diabetes mellitus
- •4\. Patients with decompensated liver disease or renal disease
- •5\. Pregnancy or lactation
- •6\. Patients with multiorgan failure
- •7\. Patients undergoing home quarantine during treatment of mild or very mild COVID 19
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Assessment of indication and efficacy of anti-viral therapy based on mucosal PCR assay in active UC patients with CMV infection.lcerative colitisJPRN-UMIN000022588Department of Gastroenterology and Hepatology, Kyoto University Hospital120
Completed
Not Applicable
Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantatiohepatitis C after liver transplantationJPRN-UMIN000014583Kyoto University Hospital30
Completed
Not Applicable
Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for hepatitis C after organ transplantation -Pilot Studyhepatitis C after transplantationJPRN-UMIN000016558Trasnplantation surgery, Hiroshima University Hospital20
Recruiting
Not Applicable
Analysis of efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantatiohepatitis C after liver transplantationJPRN-UMIN000009171Kyoto University Hospital20
Recruiting
Not Applicable
Analysis of efficacy and safety of antiviral therapy with simeprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantatiohepatitis C after liver transplantationJPRN-UMIN000012219Kyoto University Hospital30